While IL-8 could be useful as a biomarker in multiple hematologic malignancies and could be a promising therapeutic target for MDS and AML, no clinical trials have been initiated targeting IL-8 or its downstream mediators. This evidence concerns the gene CXCL8 and acute myeloid leukemia.